Want to see TEM full AI Analyst Report?
TEM Stock Chart & Stats
$42.69
-$3.32(-7.22%)
At close: 4:00 PM EDT
$42.69
-$3.32(-7.22%)
Day’s Range― - ―
52-Week Range$40.77 - $104.32
Previous CloseN/A
Volume5.79M
Average Volume (3M)5.68M
Market Cap
$9.80B
Enterprise Value$11.19K
Total Cash (Recent Filing)$815.99M
Total Debt (Recent Filing)$1.44B
Price to Earnings (P/E)―
Beta3.20
Next Earnings
Nov 10, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding175,390,960
10 Day Avg. Volume4,879,393
30 Day Avg. Volume5,678,843
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-41.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$62.15Price Target Upside45.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$1.60B
Bulls Say, Bears Say
Bulls Say
Revenue Scale & Gross MarginTempus has durable top-line scale and high gross margins (~70%), showing its core diagnostics and data products generate strong unit economics. Large recurring revenue from clinical testing and licensing supports long-term margin sustainability as volume and data monetization expand.
Proprietary Data Assets & Pharma PartnershipsA >500PB multimodal clinico-molecular dataset and GPU-enabled model platform create a durable data moat and network effects. Deep pharma collaborations (Merck, Gilead, AstraZeneca model delivery) reinforce sticky, high-value licensing and long-term product differentiation versus smaller competitors.
Improving EBITDA Trajectory & Contract VisibilityManagement's upgraded guide and quarter-over-quarter EBITDA improvement reflect durable operating leverage as data licensing and large multi-year pharma deals (>$100M bookings) scale. Meaningful TCV visibility supports a credible path toward sustained positive operating cash flow over months to years.
Bears Say
High LeverageA materially elevated debt load (debt > equity) constrains financial flexibility, raises servicing risk and limits ability to absorb shocks or fund organic growth without dilution or further borrowing. This structural leverage pressure persists until consistent positive free cash flow is established.
Negative Cash GenerationPersistent negative operating and free cash flow implies ongoing reliance on external financing for growth and M&A. Even with improving EBITDA trends, continued cash burn risks interest and refinancing exposure and can force tradeoffs between R&D, commercialization and margin improvement priorities.
Acquisition, Reimbursement & Regulatory Execution RiskThe Personalis acquisition is structurally significant but brings execution and regulatory risk plus integration demands. MRD reimbursement and FDA timing uncertainty can prolong cash burn and delay value capture, making strategic benefits contingent on approvals and successful commercial scale-up.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $40.77 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $9.80B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Nov 10, 2026 which is in 87 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Jul 30, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.103.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.07.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 175,390,960 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went down -0.948%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.15 (45.59% Upside)
$62.15 (45.59% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 95%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.56%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong topline momentum and durable demand in both diagnostics and data/applications: revenue growth (~36% YoY), robust Data & Insights growth (40.5% YoY; Insights >44%), expansion of large pharma collaborations (Merck, Gilead), rising bookings/TCV and an upgraded full-year revenue guide to $1.59B–$1.60B with adjusted EBITDA targeted at ~$65M. Key risks and near-term headwinds include Q1 cash-flow timing effects, slower hereditary volumes early in the year, MRD reimbursement and scaling constraints, and some regulatory timing uncertainty. Overall the positives (strong growth, expanding high-value contracts, improving EBITDA trajectory and sizable data assets) outweigh the transitory operational and reimbursement challenges.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$62.15
▲(45.59% Upside)
Technical Analysis
Ownership Overview
22.17% Insiders
8.84% Mutual Funds
26.78% Other Institutional Investors
26.33% Public Companies and Individual Investors